By Counterforce Health Team in Xenpozyme (olipudase alfa-rpcp) —

How to Get Xenpozyme (olipudase alfa-rpcp) Covered by Aetna (CVS Health) in Florida: Complete Appeals Guide with Templates

Answer Box: Getting Xenpozyme Covered by Aetna (CVS Health) in Florida

Xenpozyme (olipudase alfa-rpcp) requires prior authorization from Aetna (CVS Health) with strict criteria: confirmed ASMD diagnosis via genetic testing or enzyme assay, specialist involvement, and CVS Specialty Pharmacy dispensing. Fastest approval path: 1) Ensure genetic/enzyme confirmation is documented, 2) Have your ASMD specialist complete the Lysosomal Storage Disorders Enrollment Form, 3) Submit through CVS Specialty at 1-800-237-2767. If denied, Florida law gives you 180 days to appeal with 30-day decision timelines under the 2024 Patient Timely Access to Healthcare Act. Start your internal appeal immediately while gathering clinical documentation.

Table of Contents

  1. Understanding Aetna's Xenpozyme Coverage Requirements
  2. Reading Your Denial Letter
  3. Common Denial Reasons & How to Fix Them
  4. Step-by-Step Appeals Process in Florida
  5. Medical Necessity Letter Template
  6. Peer-to-Peer Call Strategy
  7. External Review Process
  8. Cost Assistance Options
  9. When to Escalate to State Regulators
  10. FAQ

Understanding Aetna's Xenpozyme Coverage Requirements

Aetna (CVS Health) covers Xenpozyme for acid sphingomyelinase deficiency (ASMD), but only after meeting specific prior authorization criteria established in their Clinical Policy Bulletin 0442.

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required before dispensing CVS Specialty enrollment Aetna Precert List
Genetic Confirmation SMPD1 gene testing or enzyme assay Lab reports in medical record Aetna Policy 0442
Specialist Involvement ASMD/metabolic disease expert Provider credentials Aetna Policy 0442
CVS Specialty Only No other pharmacy allowed CVS Specialty enrollment CVS Specialty Form
Site of Care Infusion center required Aetna network directory Infusion Site Policy

Reading Your Denial Letter

When Aetna denies Xenpozyme coverage, your denial letter will include specific reason codes. Here's how to decode them:

Common denial codes and meanings:

  • "Not medically necessary" - Missing clinical documentation or ASMD diagnosis confirmation
  • "Non-formulary" - Drug not on preferred list; requires formulary exception
  • "Site of care restriction" - Must use approved infusion center
  • "Pharmacy restriction" - Must fill through CVS Specialty
Tip: Your denial letter must include appeal instructions and deadlines per Florida law. If these are missing, contact Aetna member services immediately at the number on your insurance card.

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn Required Documents
No ASMD diagnosis confirmed Submit genetic testing or enzyme assay Lab reports showing SMPD1 variants or ASM deficiency
Not prescribed by specialist Transfer care or get consultation Letter from metabolic/lysosomal specialist
Missing enrollment form Complete CVS Specialty paperwork Lysosomal Storage Form
Quantity/dosing concerns Provide weight-based dosing rationale Prescriber's dosing calculation and monitoring plan
Site of care issue Confirm in-network infusion center Facility network status verification

Step-by-Step Appeals Process in Florida

Under Florida's 2024 Patient Timely Access to Healthcare Act, Aetna must follow accelerated timelines for appeals decisions.

Internal Appeal (Level 1)

  1. File within 180 days of denial notice
  2. Submit in writing to address on denial letter
  3. Include all supporting documents: medical records, lab results, specialist letters
  4. Aetna must decide within 30 days (expedited: 4 business days for urgent cases)
  5. Track your submission with certified mail or portal confirmation

Required Documents for Appeal

  • Copy of denial letter
  • Medical necessity letter from prescriber
  • ASMD diagnostic confirmation (genetic/enzyme testing)
  • Clinical notes documenting disease progression
  • Prior treatment history and failures (if applicable)

Medical Necessity Letter Template

Your ASMD specialist should include these elements in their medical necessity letter:

Essential Components

Patient Information Section:

  • Full name, date of birth, policy number
  • ASMD diagnosis with ICD-10 code E75.24
  • Date of diagnosis and confirming tests

Clinical Rationale:

[Patient Name] has been diagnosed with acid sphingomyelinase deficiency (ASMD), 
confirmed by [genetic testing showing SMPD1 variants / enzyme assay showing 
deficient activity]. Current manifestations include [list specific symptoms: 
hepatosplenomegaly, pulmonary involvement, hematologic abnormalities].

Xenpozyme (olipudase alfa-rpcp) is the only FDA-approved enzyme replacement 
therapy for non-CNS manifestations of ASMD. Clinical trials demonstrate 
significant reductions in spleen and liver volume, with improvements in 
pulmonary function and platelet counts.

Without treatment, ASMD is progressive and life-threatening. This patient's 
current [symptom severity] warrants immediate initiation of enzyme replacement 
to prevent irreversible organ damage.

Supporting Evidence:

  • Reference FDA approval and prescribing information
  • Cite clinical trial data (ASCEND studies)
  • Include baseline organ measurements and lab values
From our advocates: We've seen the strongest medical necessity letters include specific organ measurements (spleen volume in multiples of normal, liver span) and trending lab values showing disease progression. Quantifiable data helps medical reviewers understand urgency better than symptom descriptions alone.

Peer-to-Peer Call Strategy

If your initial appeal is denied, request a peer-to-peer review where your specialist can discuss the case directly with Aetna's medical director.

Preparation Checklist

  • Medical records organized chronologically
  • Diagnostic test results highlighted
  • FDA prescribing information printed
  • Clinical trial references ready
  • Patient's current symptoms and progression documented

Key Talking Points

  1. ASMD is a rare, progressive, life-threatening disease
  2. Xenpozyme is the only FDA-approved treatment
  3. Patient meets all diagnostic criteria per Aetna's own policy
  4. Delay in treatment risks irreversible organ damage
  5. Alternative treatments don't exist for the underlying enzyme deficiency

External Review Process

If Aetna denies your internal appeal, Florida law provides external review through independent medical experts.

Florida External Review Process

  • Timeline: Request within 4 months of final internal denial
  • Decision timeframe: Standard cases: 30 days; Urgent cases: 4 business days
  • Cost: Free to patients
  • Authority: Florida Department of Financial Services
  • Binding: Aetna must cover if external reviewer approves

To request external review:

  1. Call Florida's Insurance Consumer Helpline: 1-877-693-5236
  2. Submit complaint online through DFS consumer portal
  3. Include all denial letters and medical documentation

Cost Assistance Options

While pursuing coverage, explore financial assistance programs:

Manufacturer Support

  • The Assistance Fund (TAF) provides copay assistance for eligible ASMD patients
  • Eligibility: U.S. residency, confirmed diagnosis, insurance coverage, income limits
  • Application: Through National Niemann-Pick Disease Foundation

Additional Resources

  • State pharmaceutical assistance programs
  • Hospital charity care programs
  • Clinical trial participation (if available)

Counterforce Health helps patients navigate complex insurance appeals for specialty medications like Xenpozyme. Our platform analyzes denial letters and generates targeted, evidence-based appeals that align with payer policies. By combining clinical expertise with insurance knowledge, we help patients get life-saving treatments approved faster.

When to Escalate to State Regulators

Contact Florida regulators if Aetna:

  • Misses legal deadlines for appeal decisions
  • Requests inappropriate documentation
  • Denies coverage despite meeting policy criteria
  • Fails to provide required appeal information

Florida Department of Financial Services

FAQ

Q: How long does Aetna's prior authorization process take in Florida? A: Standard PA decisions typically take 7-14 days. Urgent requests can be expedited to 24-72 hours with proper clinical justification.

Q: What if Xenpozyme isn't on Aetna's formulary? A: You can request a formulary exception by demonstrating medical necessity and lack of appropriate alternatives on the preferred drug list.

Q: Can I request an expedited appeal? A: Yes, if delay in treatment could seriously jeopardize your health. Florida law requires expedited appeals to be decided within 4 business days.

Q: Does step therapy apply to Xenpozyme? A: No, since Xenpozyme is the only FDA-approved treatment for ASMD, step therapy requirements typically don't apply.

Q: What happens if I move from another state to Florida during treatment? A: Your Aetna plan may have different requirements in Florida. Contact member services to confirm continued coverage and any new documentation needed.

Q: How often do I need reauthorization? A: Most Aetna plans require reauthorization every 6-12 months with documentation of continued clinical benefit and medical necessity.

Need help navigating your specific Xenpozyme appeal? Counterforce Health specializes in turning insurance denials into successful approvals through targeted, evidence-based appeals that speak directly to payer policies and clinical guidelines.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage varies by plan and individual circumstances. Always consult with your healthcare provider and insurance company for specific guidance regarding your coverage and treatment options. For regulatory assistance in Florida, contact the Department of Financial Services at 1-877-693-5236.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.